Login to Your Account



Dynavax's Stock Jumps On Positive Allergy Drug Data

By Jennifer Boggs


Friday, January 20, 2006
Shares of Dynavax Technologies Corp. jumped 34 percent after the company reported two-year data from a Phase II/III trial showing that its disease-modifying allergy drug, Tolamba, significantly reduced symptoms compared to placebo. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription